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See Article, pages 705–715In hepatocellular carcinoma (HCC), heterogeneity is a well known
biological feature reﬂecting the diverse etiological factors and the
different geographical sites of development of the disease [1].
Identiﬁcation of the tumor’s molecular singularities is an impor-
tant issue to improve the efﬁcacy of molecular therapies in HCC.
As in other types of solid tumors, numerous genetic, and epige-
netic alterations accumulate during hepatocarcinogenesis that
lead to misregulation of mRNA and miRNA proﬁles. While several
laboratories have concentrated their research on the comprehen-
sive characterization of structural DNA damage (such as point
mutations and chromosomal rearrangements) in HCC in relation
to clinical parameters, the study of the role of epigenetic events
in HCC needs to be further explored as they are key drivers of spe-
ciﬁc tumoral processes. Epigenetic alterations are deﬁned as her-
itable changes in gene expression that are not due to any
alteration in the DNA sequence. They consist of modiﬁcation of
DNA methylation and of post-translational modiﬁcations of his-
tones that change the chromatin structure and promoter activity
(Fig. 1). Currently, in cancer, the best studied epigenetic marker
is DNAmethylation. Twomain modiﬁcations have been described
in tumors, a genome wide DNA hypomethylation that might
contribute to the generation of chromosomal instability, the reac-
tivation of transposable elements or the loss of imprinting, and
the hypermethylation of the CpG islands in the promoter regions
of tumor suppressor genes that leads to their inactivation [2]. All
these epigenetic events lead to either activation of oncogenes or to
the loss of function of tumor suppressor genes [3]. Furthermore,
epigenetic abnormalities are potentially reversible in contrast to
genemutations, and different compounds that act as either deme-
thylating agents or histone deacetylase inhibitors are available for
the design of an epigenetic therapy of cancer.
The article of Lambert et al. analyzed the status of DNA meth-
ylation in human HCC with the objective of identifying epigenetic
biomarkers of clinical interest. The authors used a quantitative
analysis of DNA methylation based on pyrosequencing to evalu-
ate the methylation level of a selected panel of seven-cancer-
associated genes and repetitive elements in a large series of
HCC tumors associated with major risk factors and collected from
two different geographical areas. They observed that in all theJournal of Hepatology 20
qDOI of original article: 10.1016/j.jhep.2010.07.027.
E-mail address: perret@cochin.inserm.frHCC samples studied the methylation level of the repetitive
LINE-1 element was always lower in HCC tumors than in cirrhotic
or normal liver tissues, and was not associated with any speciﬁc
risk factors supporting the global DNA hypomethylation already
described in hepatocellular carcinogenesis [4]. They also found
an aberrant hypermethylation of the RASSF1A (Ras association
domain family member 1) and GSTP1 (glutathione S-transferase
pi 1) genes in accordance with previous data [5–7]. Altogether
these results revealed the accuracy of their technical approach.
The novelty of this study was the identiﬁcation of a speciﬁc set
of genes that bore an aberrant hypermethylation restricted to
the HCC tumor, and not present in the cirrhotic or normal liver
tissue. Moreover, this aberrant hypermethylation was associated
with the repression of gene expression that was reversed after
treatment by a demethylating agent. But more importantly, the
authors show that the methylation pattern could be used as a sig-
nature for exposure to risk factors. Methylation levels of GSTP1
were signiﬁcantly higher in HCC tumors from HBV-positive
patients than those without HBV infection, and higher levels of
MGMT (O-6-methylguanine-DNA methyltransferase) gene meth-
ylation were signiﬁcantly observed in alcohol-associated HCC.
Thus, the methylation status of the GSTP1 and MGMT genes
appears as epigenetic biomarkers of human HCC. Epigenetic
alterations allow the cancer cells to adapt to changes in its micro-
environment and identiﬁcation in alcohol-associated HCC, of a
speciﬁc high frequency of hypermethylation of the DNA repair
gene, MGMT, offers a new path to comprehend how alcohol
may be tumorigenic in the liver.
However, the strength of this data would be reinforced if they
were combined with the recent new data of the molecular classiﬁ-
cation of HCC [8–10]. Chromosome instability appears to be a main
driver of tumor classiﬁcation and at least two different HCC sub-
groups have been identiﬁed that distinguished two different ways
of development for hepatocarcinogenesis: HCC that develop in a
context of high genomic instability mainly observed in HBV-
infected patients and HCC that develop in a stable chromosome
context. Deﬁning the epigenetic alterations is clearly an important
issue to address in order to determine the different pathways of
hepatocellular tumor pathogenesis; moreover, it will also lead to
a better reﬁnement of the molecular classiﬁcation of HCC.
The results of Lambert et al., are a ﬁrst step, when extended to
a larger set of genes, to a comprehensive study of the HCC11 vol. 54 j 602–603
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Fig. 1. In normal cells, the CpG islands present in the promoter region of a
tumor suppressor gene (TSG) are unmethylated and chromatin is active
allowing expression of the TSG gene. In cancer cells, heritable silencing of TSG is
associated with the deposition of new epigenetic markers and results in CpG
methylation of the TSG promoter. This de novo DNA methylation involves a
complex interplay between enzymes that methylate DNA and modify histones
leading to DNA remodelling and silencing of the TSG. Adapted from [3].
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ued improvements of mRNA, miRNA, genetic, and epigenetic
(e.g., whole DNA methylome proﬁles and histone-modiﬁcation
maps) studies, the integrative analyses of all these data will
increase our knowledge of molecular subclasses of HCC to iden-
tify which patients will beneﬁt best from certain compounds,
an important step towards personalized medicine in the treat-
ment of HCC.Conﬂict of interest
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